Interval Between Colonoscopies May Be Lengthened For Some Colorectal Cancer Patients, Ochsner Study Concludes

Publication
Article
OncologyONCOLOGY Vol 10 No 8
Volume 10
Issue 8

The interval between follow-up colonoscopies may be increased from 1 to 3 years for colorectal cancer patients whose examinations are negative after 2 years, concludes a study of 389 patients at the Ochsner Clinic, New Orleans, Louisianna,

The interval between follow-up colonoscopies may be increasedfrom 1 to 3 years for colorectal cancer patients whose examinationsare negative after 2 years, concludes a study of 389 patientsat the Ochsner Clinic, New Orleans, Louisianna, reported inDiseases of the Colon & Rectum (DC&R).

"We believe this recommendation outlines appropriate andcost-effective colon surveillance guidelines for colorectal cancerpatients and will help decrease the total number of normal surveillanceexaminations," write Ochnser's Douglas A. Khoury, MD, FrankG. Opelka, MD, David E. Beck, MD, Terry C. Hicks, MD, Alan E.Timmcke, MD, and J. Byron Gathright, Jr., MD.

Current guidelines of the American Society of Colon and RectalSurgeons (ASCRS) recommend annual colonoscopies for up to 5 yearsafter a patient has surgery for colorectal cancer.

Reoperation Plus Surgery for Local Recurrence of Recal Carcinoma

Another study reported in the March issue of DC&R offers increasedhope for patients who experience a local recurrence of cancerafter surgery for rectal cancer. "In selected patients withlocal recurrence of rectal carcinoma, reoperation with irradiationmay result in good palliation and possibly cure," reportTheoWiggers, MD, PhD, Mark R. de Vries, MD, and Bernadette Veeze-Kuypers,MD, of the Departments of Surgical Oncology and Radiotherapy atDr. Daniël den Hoed Cancer Center in Rotterdam, The Netherlands.

Surgery is the most effective treatment for colorectal cancer.Even when all visible cancer has been removed, it is possiblefor cancer cells to be present in other areas of the body. Thechance of recurrence depends on the characteristics of the originalcancer and the effectiveness of chemotherapy or radiation, ifneeded, or other follow-up treatment. Patients with recurrentcancers--if diagnosed early--may benefit, or be cured, by furthersurgery or other treatment.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Related Content